Cited by 640Potassium and Related DisordersRenin-Angiotensin System StudiesCoagulation, Bradykinin, Polyphosphates, and Angioedema

The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index, and 1 are not checked yet.

Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system

Palmer, Biff F.·2004·New England Journal of Medicine

DOI 10.1056/nejmra035279

Open this paper in CoChat — free account

Abstract

Hyperkalemia can develop as a result of treatment with angiotensin-converting–enzyme inhibitors or angiotensin-receptor blockers. This side effect is most common in patients with risk factors such as diabetes mellitus, heart failure, chronic kidney disease, or advanced age. This review explains the pathophysiology and offers clinical guidance for management.

Integrity signals

Registry

Crossref · 10.1056/nejmra035279

Cites

59 of 60 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 retracted

RETRACTED: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial
Nakao, N., Yoshimura, A., Morita, H., Takada, M., Kayano, T., & Ideura, T. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12229-5 · Cited by 947
Retracted
A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F. M., Remme, W. J., Cody, R. J., Castaigne, A., Pérez, A. J. P., Palensky, J., & Wittes, J. T. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial
McMurray, J. J., Östergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer, M. A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14283-3 · Cited by 2,604
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
Pfeffer, M. A., McMurray, J. J. V., Velazquez, E. J., Rouleau, J.-L., Køber, L., Maggioni, A. P., Solomon, S. D., Swedberg, K., Van de Werf, F., White, H., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032292 · Cited by 2,471
Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study
Juurlink, D. N., Mamdani, M. M., Lee, D. S., Kopp, A., Austin, P. C., Laupacis, A., & Redelmeier, D. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040135 · Cited by 1,761
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
Lindholm, L. H., Ibsen, H., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Kristiansson, K., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08090-x · Cited by 1,560
Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
Yusuf, S., & Jha, P. (2000) · Cited by 895
Herbal Medicinals: Selected Clinical Considerations Focusing on Known or Potential Drug-Herb Interactions
Miller, L. G. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.20.2200 · Cited by 809
Drug-Drug Interactions Among Elderly Patients Hospitalized for Drug Toxicity
Juurlink, D. N., Mamdani, M., Kopp, A., Laupacis, A., & Redelmeier, D. A. (2003) · JAMA · doi:10.1001/jama.289.13.1652 · Cited by 766
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
Brenner, B. M., Cooper, M. E., & de Zeeuw, D. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00549-9 · Cited by 512
Renal Dysfunction Complicating the Treatment of Hypertension
Palmer, B. F. (2002) · New England Journal of Medicine · doi:10.1056/nejmra020676 · Cited by 330
Self-citation
Hyperkalemia in Hospitalized Patients
Acker, C. G., Johnson, J. P., Palevsky, P. M., & Greenberg, A. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.8.917 · Cited by 325
Hyperkalemia and hyporeninemic hypoaldosteronism
DeFronzo, R. A. (1980) · Kidney International · doi:10.1038/ki.1980.14 · Cited by 323
Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases
Schepkens, H., Vanholder, R. C., Billiouw, J.-M., & Lameire, N. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00642-8 · Cited by 255
Drug-induced hyperkalemia: old culprits and new offenders
Perazella, M. A. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00496-4 · Cited by 251
Hyperkalemia in Outpatients Using Angiotensin-Converting Enzyme Inhibitors: How Much Should We Worry?
Reardon, L. C., & Macpherson, D. S. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.1.26 · Cited by 222
Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines
Bozkurt, B., Agoston, I., & Knowlton, A. A. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02694-3 · Cited by 221
Management of Glomerular Proteinuria: A Commentary
Wilmer, W. A., Rovin, B. H., Hebert, C. J., Rao, S. V., Kumor, K., & Hebert, L. A. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000100145.27188.33 · Cited by 217
Upper Gastrointestinal Tract Injury in Patients Receiving Kayexalate (Sodium Polystyrene Sulfonate) in Sorbitol
Abraham, S. C., Bhagavan, B. S., Lee, L. A., Rashid, A., & Wu, T. (2001) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200105000-00011 · Cited by 216
Heparin-induced aldosterone suppression and hyperkalemia
Oster, J. R., Singer, I. I., & Fishman, L. M. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80017-5 · Cited by 205
Pharmacotherapy for Heart Failure in Patients with Renal Insufficiency
Shlipak, M. G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-11-200306030-00013 · Cited by 167
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure
Cohn, J. N., & Tognoni, G. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00651-7 · Cited by 149
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both
Pfeffer, M. A., McMurray, J. J. V., & Velazquez, E. J. (2004) · ACC Current Journal Review · doi:10.1016/j.accreview.2003.12.039 · Cited by 147
Aldosterone in Chronic Kidney and Cardiac Disease
Hostetter, T. H., & Ibrahim, H. N. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000086472.65806.73 · Cited by 137
Hyperkalemia as a Complication of Drug Therapy
Rimmer, J. M. (1987) · Archives of Internal Medicine · doi:10.1001/archinte.1987.00370050063011 · Cited by 128
Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors
Ahuja, T. S., Freeman Jr., D., Mahnken, J. D., Agraharkar, M., Siddiqui, M., & Memon, A. (2000) · American Journal of Nephrology · doi:10.1159/000013599 · Cited by 114
Studies to determine the basis for hyperkalemia in recipients of a renal transplant who are treated with cyclosporine.
Kamel, K. S., Ethier, J. H., Quaggin, S. E., Levin, A. S., Albert, S., Carlisle, E., & Halperin, M. L. (1992) · Journal of the American Society of Nephrology · doi:10.1681/asn.v281279 · Cited by 110
A Mechanism for Pentamidine-Induced Hyperkalemia: Inhibition of Distal Nephron Sodium Transport
Kleyman, T. R., Roberts, C., & Ling, B. N. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-2-199501150-00004 · Cited by 93
Noni juice (Morinda citrifolia ): Hidden potential for hyperkalemia?
Mueller, B. A., Scott, M. K., Sowinski, K. M., & Prag, K. A. (2000) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(00)70342-8 · Cited by 91
Clinical and demographic predictors of exercise capacity in end-stage renal disease
Sietsema, K. E., Hiatt, W. R., Esler, A. L., Adler, S. G., Amato, A., & Brass, E. P. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.29884 · Cited by 90
Renal complications associated with use of nonsteroidal anti-inflammatory agents.
Palmer, B. F. (1995) · PubMed · Cited by 89
Self-citation
Angiotensin converting enzyme inhibition in chronic allograft nephropathy
Lin, J., Valeri, A. M., Markowitz, G. S., Agati, V. D. R., Cohen, D. J., & Radhakrishnan, J. (2002) · Transplantation · doi:10.1097/00007890-200203150-00022 · Cited by 74
Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone
Cruz, C. S. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg295 · Cited by 71
Attenuation of Angiotensin II- and III-induced Aldosterone Release by Prostaglandin Synthesis Inhibitors
Campbell, W. B., Gómez-Sánchez, C. E., Adams, B. V., Schmitz, J. M., & Itskovitz, H. D. (1979) · Journal of Clinical Investigation · doi:10.1172/jci109615 · Cited by 60
Production of Renin, Angiotensin II, and Aldosterone by Adrenal Explant Cultures: Response to Potassium and Converting Enzyme Inhibition*
Shier, D. N., KUSANO, E., Stoner, G. D., Franco-Saenz, R., & Mulrow, P. J. (1989) · Endocrinology · doi:10.1210/endo-125-1-486 · Cited by 57
Acute Abdomen With Colonic Necrosis Induced by Kayexalate-Sorbitol
Dardik, A., Moesinger, R. C., Efron, G., Barbul, A., & HARRISON, M. G. (2000) · Southern Medical Journal · doi:10.1097/00007611-200005000-00016 · Cited by 57
Multiplicative interaction between angiotensin II and K concentration in stimulation of aldosterone
Young, D. B., Smith, M. J., Jackson, T. E., & Scott, R. E. (1984) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1984.247.3.e328 · Cited by 55
Hyperkalemia and Renal Insufficiency: Role of Selective Aldosterone Deficiency and Tubular Unresponsiveness to Aldosterone
Arruda, J. A. L., BATLLE, D. C., Sehy, T., Roseman, M. K., Baronowski, R. L., & Kurtzman, N. A. (2008) · American Journal of Nephrology · doi:10.1159/000166533 · Cited by 53
Incidence of hyperkalaemia induced by indomethacin in a hospital population.
Zimran, A., Kramer, M. R., Plaskin, M., & Hershko, C. (1985) · BMJ · doi:10.1136/bmj.291.6488.107 · Cited by 49
Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction
Ray, K. K., Dorman, S., & Watson, R. (1999) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1000890 · Cited by 48
Evidence that Angiotensin-II and Potassium Collaborate to Increase Cytosolic Calcium and Stimulate the Secretion of Aldosterone*
Pratt, J. H., Rothrock, J. K., & Dominguez, J. H. (1989) · Endocrinology · doi:10.1210/endo-125-5-2463 · Cited by 39
Labetalol-Induced Hyperkalemia in Renal Transplant Recipients
McCauley, J., Murray, J., Jordan, M. L., Scantlebury, V. P., Vivas, C., & Shapiro, R. (2002) · American Journal of Nephrology · doi:10.1159/000065225 · Cited by 39
FREQUENCY OF HYPERKALEMIA IN RECIPIENTS OF SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTS WITH BLADDER DRAINAGE
Kaplan, B. E., Wang, Z., Abecassis, M. M., Fryer, J. P., Stuart, F. P., & Kaufman, D. B. (1996) · Transplantation · doi:10.1097/00007890-199610270-00025 · Cited by 36
Fatal hyperkalemia related to combined therapy with a COX-2 inhibitor, ACE inhibitor and potassium rich diet
Hay, E., Derazon, H., Natalia, B., Katz, L., Kruglyakov, I., & Armoni, M. (2002) · Journal of Emergency Medicine · doi:10.1016/s0736-4679(02)00434-1 · Cited by 33
Herbal Interactions With Cardiac Drugs
Cheng, T. O. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.6.870 · Cited by 32
A subdepressor low dose of ramipril lowers urinary protein excretion without increasing plasma potassium
Keilani, T., Danesh, F. R., Schlueter, W. A., Molteni, A., & BATLLE, D. C. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70181-2 · Cited by 28
TRIMETHOPRIM IS A POTASSIUM-SPARING DIURETIC LIKE AMILORIDE AND CAUSES HYPERKALEMIA IN HIGH-RISK PATIENTS
Perazella, M. A. (1997) · American Journal of Therapeutics · doi:10.1097/00045391-199709000-00010 · Cited by 27
Effect of aging on renal function and disease
Mohamed, M. M. A. A. (2002) · Cited by 24
Adrenergic modulation of potassium metabolism during exercise in normal and diabetic humans
Castellino, P., Simonson, D. C., & DeFronzo, R. A. (1987) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1987.252.1.e68 · Cited by 23
Spironolactone and congestive heart-failure
Georges, B., Beguin, C., & Jadoul, M. Y. (2000) · The Lancet · doi:10.1016/s0140-6736(05)72606-4 · Cited by 20
Hyperkalemia as a complication of drug therapy
Rimmer, J. M. (1987) · Archives of Internal Medicine · doi:10.1001/archinte.147.5.867 · Cited by 12
Drug-induced hyperkalemia
Pantanowitz, L. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00688-x · Cited by 11
High cytosolic pH inhibits Ca uptake by Myxicola axon mitochondria
Abercrombie, R. F., & Gammeltoft, K. (1987) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1987.252.1.c68 · Cited by 10

Research works printed but not linked: 4

Young DB, 1984, Am J Physiol, 247, E328
Palmer BF, 1995, J Investig Med, 43, 516
1995, MMWR Morb Mortal Wkly Rep, 44, 853
Dardik A, 2000, South Med J, 93, 511, 10.1097/00007611-200093050-00016 · DOI

Sorted by citations

KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Business Information
Rodbard, H. W., Blonde, L., Ss, B., Brett, E. M., Cobin, R. H., Handelsman, Y., Hellman, R., Jellinger, P. S., Jovanovic, L. G., Levy, P., et al. (2007) · Endocrine Practice · doi:10.4158/ep.13.s1.1 · Cited by 695
Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors
Weir, M. R., Bakris, G. L., Bushinsky, D. A., Mayo, M. R., Garza, D., Stasiv, Y., Wittes, J. T., Christ‐Schmidt, H., Berman, L., & Pitt, B. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1410853 · Cited by 683
The Frequency of Hyperkalemia and Its Significance in Chronic Kidney Disease
Einhorn, L. M., Zhan, M., Hsu, V. D., Walker, L. D., Moen, M. F., Seliger, S. L., Weir, M. R., & Fink, J. C. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.132 · Cited by 655

See all 640

Authors: Palmer, B. F.
Affiliations: The University of Texas Southwestern Medical Center (US)
Corresponding author: Palmer, Biff F.
ORCID: Palmer, Biff F.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2004-08-05
Volume: 351
Issue: 6
Pages: 585-592
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmra035279
OpenAlex: W2093767567
Semantic Scholar: 58d9c67c801fe4f1082d485f5f4497ed175693d9
Cited by: 640
References: 59
Citations by year: 2026: 19 · 2025: 29 · 2024: 28 · 2023: 28 · 2022: 24 · 2021: 23 · 2020: 34 · 2019: 28 · 2018: 35 · 2017: 42 · 2016: 31 · 2015: 28 · 2014: 30 · 2013: 21 · 2012: 37
FWCI: 4.89
Type: journal article
Language: en
Open access: closed
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Nephrology › Potassium and Related Disorders
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
Health Sciences › Medicine › Hematology › Coagulation, Bradykinin, Polyphosphates, and Angioedema
Keywords: hyperkalemia, renin-angiotensin-aldosterone system inhibitors, ACE inhibitors, angiotensin receptor blockers, drug-induced hyperkalemia, pathophysiology, diabetes mellitus, heart failure, chronic kidney disease, elderly patients, hyperkalemia management
MeSH terms: Aldosterone, Angiotensin-Converting Enzyme Inhibitors, Humans, Hyperkalemia, Kidney, Potassium, Renin-Angiotensin System, Risk Factors, Sodium, Angiotensin Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks